16 September 2014
EMEA/H/C/003824

Public statement

Rivastigmine 3M Health Care Ltd

Withdrawal of the marketing authorisation in the European Union

On 19 August 2014, the European Commission withdrew the marketing authorisation for Rivastigmine 3M Health Care Ltd (rivastigmine, transdermal patches) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, 3M Health Care Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Rivastigmine 3M Health Care Ltd was granted marketing authorisation in the EU on 3 April 2014 for the treatment of mild to moderately severe Alzheimer's dementia.

Rivastigmine 3M Health Care Ltd is a generic medicine of Exelon. There are other generic medicinal products of Exelon authorised and marketed in the EU. Rivastigmine 3M Health Care Ltd. is an identical product to Rivastigmine Actavis (transdermal patches), which is authorised in the EU to treat patients with mild to moderately severe Alzheimer's dementia. Rivastigmine 3M Health Care Ltd was a duplicate application to Rivastigmine Actavis Transdermal Patches.

The European Public Assessment Report (EPAR) for Rivastigmine 3M Health Care Ltd will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact